![]() |
市場調查報告書
商品編碼
1319878
全球單克隆抗體在獸醫保健市場研究報告 - 2023 年至 2030 年行業分析、規模、佔有率、成長、趨勢和預測Global Monoclonal Antibodies In Veterinary Health Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030 |
全球獸醫保健市場對單克隆抗體的需求預計將從 2022 年的 718.09 萬美元達到 2030 年近 2741.58 萬美元的市場規模,2023-2030 年研究期間複合年複合成長率為 18.23%。
獸醫保健中的單克隆抗體(mAb)是指用於動物治療各種疾病和病症的一種靶向療法。這些是實驗室生產的分子,旨在模仿免疫系統響應感染或其他異物而產生的天然抗體。
動物中癌症和自身免疫性疾病等慢性疾病的患病率正在上升,這推動了單克隆抗體等靶向和特異性療法的採用。生物技術和基因工程的進步也提高了單克隆抗體的生產,提供更有效和專業的治療。獸醫的認知和接受度不斷提高,加上臨床試驗的積極結果,促進了它們的普及。不斷擴大的獸藥行業、對個性化和標靶治療的關注以及伴侶動物護理的改善進一步增加了對這些抗體的需求。此外,監管部門的批准以及研究機構和製藥公司之間的合作加速了單克隆抗體在獸醫健康領域的開發和可及性。隨著技術的成熟和成本變得更加易於管理,市場預計將持續成長,為動物提供新的和創新的治療選擇。
該研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外,這些工具還對全球獸醫健康單克隆抗體市場的各個細分市場進行了包容性評估。獸醫保健行業單克隆抗體的成長和趨勢為本研究提供了整體方法。
本節涵蓋區域前景,重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲獸醫保健市場單克隆抗體當前和未來的需求。此外,該報告重點關注所有主要地區各個應用領域的需求、估計和預測。
該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。獸醫保健單克隆抗體市場的主要參與者包括 Zoetis、Merck & Co, Inc.、Elanco、Boehringer Ingelheim GmbH、Indian Immunologicals Ltd、Virbac。本節包含競爭格局的整體視圖,包括各種戰略發展,例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。
如果您有任何客製化要求,請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。
The global demand for Monoclonal Antibodies in Veterinary Health Market is presumed to reach the market size of nearly USD 2741.58 MN by 2030 from USD 718.09 MN in 2022 with a CAGR of 18.23% under the study period 2023 - 2030.
Monoclonal antibodies (mAbs) in veterinary health refer to a type of targeted therapy used in animals to treat various diseases and conditions. These are laboratory-produced molecules designed to mimic the natural antibodies that the immune system produces in response to infections or other foreign substances.
The prevalence of chronic diseases in animals, such as cancer and autoimmune disorders, is rising, which is driving the adoption of targeted and specific therapies like mAbs. Biotechnology and genetic engineering advancement have also improved the production of mAbs, offering more effective and specialized treatments. Growing awareness and acceptance among veterinarians, coupled with positive outcomes from clinical trials, have contributed to their popularity. The expanding veterinary pharmaceutical industry, focus on personalized and targeted therapies and improved companion animal care have further boosted the demand for these antibodies. Additionally, regulatory approvals and collaborations between research institutes and pharmaceutical companies have accelerated the development and accessibility of mAbs in veterinary health. As the technology matures and costs become more manageable, the market is expected to witness continued growth, offering new and innovative treatment options for animals.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of monoclonal antibodies in veterinary health. The growth and trends of monoclonal antibodies in veterinary health industry provide a holistic approach to this study.
This section of the monoclonal antibodies in veterinary health market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
This section covers the regional outlook, which accentuates current and future demand for the Monoclonal Antibodies in Veterinary Health market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Monoclonal Antibodies in Veterinary Health market include Zoetis, Merck & Co, Inc., Elanco, Boehringer Ingelheim GmbH, Indian Immunologicals Ltd, Virbac. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.